People In The News: Former Federal Officials On The Move; Changes At Aurinia, Neo, Mallinckrodt, Lilly, And More
Former FDA Commissioner and CMS Administrator Mark McClellan joins the Johnson & Johnson board; former CMS officials Larry Kocot, Mark Hamelburg and Thomas Hutchinson join law firm Epstein Becker & Green; ONCHIT head Farzad Mostashari heads to Brookings; Aurinia names Glickman acting CEO; more personnel moves in this month’s column.
You may also be interested in...
A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.
Plus perspectives on AstraZeneca/Pearl Therapeutics, Xenon/Isis, Questcor/Novartis, BMS/Simcere and more.
Gilfillan, who is the first director of CMS’ Center for Medicare and Medicaid Innovation, will leave CMS by the end of June after almost three years at the helm of the center established in 2010 to experiment with and help implement new health care delivery and payment models.